Navigation Links
ACRES and BSI Launch Global Working Party to Develop Standards for Clinical Research Sites
Date:12/13/2016

The Alliance for Clinical Research Excellence and Safety (ACRES), in partnership with the British Standards Institution (BSI), has announced advances in the third-phase of their global initiative to create standards for the accreditation of high-performing clinical research sites worldwide, thus promoting professionalism and excellence in clinical research while accelerating medicines development and enhancing clinical trials performance, safety and quality.

The Global Standards for Excellence (GSE) Working Party, formally launched in mid-November, brings together a team of global content experts from multiple domains to work with the BSI professional standards-writers to fast-track the development and testing of standards and metrics for assuring site excellence.

This announcement marks the continuing progress of the global accreditation effort launched by the ACRES enterprise-wide collaborative three years ago. Led by co-chairs Arti Bajpai, President, Compliance and Quality Integration (CQI) Consulting and Amir Kalali, Vice-President, Quintiles, the GSE Working Party encompasses ten cross-functional teams working across seven core domains and three specialty domains to create standards to provide the foundation for globally recognized accreditation of research sites.

Standardization and accreditation has been shown to substantially improve connectivity, interoperability, productivity, sustainability and efficiency in the conduct of clinical trials, reducing time to start-up and study completion, thereby accelerating the clinical trials process and medicines development.

Domain Team Leaders include: Anthony Rissling, CTMG, Inc.; Katie Porter, Hamilton Health Sciences; Mary Westrick, University of Wisconsin; Ivo Ivanov, AstraNova; Sara Monday, ACRES; Penny Jester, University of Alabama at Birmingham; Nadina Jose, Anidan Group Pte Ltd; Larry Kennedy, Quality Management Institute; Nonna Stepanov, Mountain State Health Alliance (MSHA) and Terry Stubbs, ActivMed Practices and Research, Inc. Steven Hirschfeld, NIH, will serve in a liaison role.

Over the next 6-9 months, the teams—each with 3-6 members bringing extensive experience in every aspect of clinical research—will work with professional standards writers from BSI to complete a set of draft standards. These will be circulated worldwide for review and comment by the entire stakeholder community--particularly research sites--but also sponsors, regulators, ethics committees, CROs, IT providers, investigators and patients. After revision based upon the comments and feedback, this initial set of standards will be pilot tested prior to a staged initiation of a unique accreditation process currently being developed in parallel with the standards.

The ACRES “Dynamic Accreditation”™ process, based upon proven high-performance models from other industries, will differ from traditional accreditation schemes by using information flowing in real-time during normal workflow to immediately identify potential challenges and opportunities for improvement, not unlike the air-traffic control feedback system utilized for global air transportation and safety.

Greg Koski, ACRES co-founder and CEO, noted that “prominent industry leaders, such as Freda Lewis-Hall, CMO at Pfizer and Briggs Morrison, CEO of Syndax Pharmaceuticals and a member of ACRES Board of Directors, have previously underscored the importance of high-performing sites in improving clinical trial performance. The standards and processes now being developed will provide an effective mechanism and incentives for sites to improve without imposing new bureaucratic and financial burdens.”

Sara Monday, ACRES VP of Site Development and Support and ACRES liaison between BSI and the teams, notes “In collaboration with BSI, our Domain teams include research professionals from around the world, each working toward one common goal: establishing standards of excellence in the clinical trials industry. This effort will bring much needed changes to our industry and will lead to the accreditation of research sites globally”.

Rob Turpin, Healthcare Market Development Manager, and Bei Ma, VP, Global Healthcare Development, are leading the BSI contribution. Turpin noted that BSI’s partnership with ACRES "takes advantage of a unique opportunity afforded by its multi-stakeholder global alliance to accelerate the development of standards that will surely enhance the entire clinical research and drug development process. We commend ACRES for its leadership of this challenging yet immensely valuable process and are delighted to be part of it.”

ACRES

The Alliance for Clinical Research Excellence and Safety (ACRES) is a non-profit alliance working in the public interest. Bringing together stakeholders spanning the clinical research ecosystem to build an open, integrated global system based in principles of Accountable Research™, ACRES adapts lessons from industries successfully implementing principles of systems and safety engineering, such as transportation, communications and information technology. For more information, please contact Mary F. Tobin, PhD, Special Advisor to the President and CEO at mtobin(at)acresglobal(dot)net

Read the full story at http://www.prweb.com/releases/GregKoskiACRES/ResearchSiteStandards/prweb13917023.htm.


'/>"/>
Source: PRWeb
Copyright©2016 Vocus, Inc.
All rights reserved


Related biology technology :

1. Interventional Concepts and ACRES Announce Alliance for Colombia
2. Former Sonavation Chief Robert Stewart to Lead ACRES Global IT Initiatives
3. ACRES Endorses MAGI’s Standard CTA Template
4. ACRES and GuideStar Collaborate on Biomedical Research Site Sustainability
5. ACRES Announces Second Phase of Collaborative IT Platform to Support Clinical Research
6. BSI and ACRES Developing Global Accreditation Standards for Clinical Research Sites
7. ACRES and ActivMed Collaborate on Clinical Research Site Standards and Sustainability
8. Briggs Morrison, CEO, Syndax Pharmaceuticals To Open ACRES Inaugural SYNERGY Event
9. Clinerion and ACRES Partner on Patient Recruitment and Risk-Based Quality Management
10. ACRES and San Antonio Express-News Launch Blog on Accountability in Clinical Research
11. ACRES Announces Innovative Clinical Research Event--SYNERGY
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2017)... , ... April 24, 2017 , ... ... thermal denaturation in a cellular milieu; however, the broad application of this cellular ... simple platforms with sensitive quantitative readouts. Cell-based thermal stabilization assays are valuable methods ...
(Date:4/21/2017)... ... April 21, 2017 , ... The University of Connecticut, ... funding to three startups through the UConn Innovation Fund. The $1.5 million UConn ... affiliated with UConn. , The UConn Innovation Fund provides investments of up to ...
(Date:4/21/2017)... ... April 21, 2017 , ... ... nourishing a range of emerging technology-based businesses, recently earned a $77,518 grant from ... , Founded in 2004, FITCI is Frederick’s first incubator. A non-profit corporation, ...
(Date:4/20/2017)... ... April 20, 2017 , ... USDM Life Sciences , ... sciences and healthcare industries, is pleased to announce Holger Braemer as Vice ... “USDM Europe GmbH” based in Germany. , Braemer is an integral part of ...
Breaking Biology Technology:
(Date:4/11/2017)... MELBOURNE, Florida , April 11, 2017 ... "Company"), a security technology company, announces the appointment of independent ... John Bendheim to its Board of Directors, furthering the ... ... behalf of NXT-ID, we look forward to their guidance and ...
(Date:4/5/2017)... , April 5, 2017 Today ... announcing that the server component of the HYPR platform ... for providing the end-to-end security architecture that empowers biometric ... HYPR has already secured over 15 million users ... including manufacturers of connected home product suites and physical ...
(Date:4/3/2017)... WASHINGTON , April 3, 2017 /PRNewswire-USNewswire/ ... single-cell precision engineering platform, detected a statistically ... cell product prior to treatment and objective ... highlight the potential to predict whether cancer ... prior to treatment, as well as to ...
Breaking Biology News(10 mins):